Cargando…
Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
PURPOSE: To evaluate the cytotoxicity of varying doses of Bevacizumab on corneal endothelial cells in the presence of a range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug widely used in the treatment of neovascular glaucoma neutralizes all isoforms of VEGF and...
Autores principales: | Rusovici, Raluca, Sakhalkar, Monali, Chalam, Kakarla V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Vision
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247162/ https://www.ncbi.nlm.nih.gov/pubmed/22219629 |
Ejemplares similares
-
Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle
por: Rusovici, Raluca, et al.
Publicado: (2013) -
The Role of Lutein in Eye-Related Disease
por: Koushan, Keyvan, et al.
Publicado: (2013) -
Ocular manifestations of Noonan syndrome in twin siblings: A case report of keratoconus with acute corneal hydrops
por: Lee, Anna, et al.
Publicado: (2014) -
Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF
por: Sharma, Rajesh K., et al.
Publicado: (2010) -
Aqueous Interleukin-6 Levels Are Superior to Vascular Endothelial Growth Factor in Predicting Therapeutic Response to Bevacizumab in Age-Related Macular Degeneration
por: Chalam, Kakarla V., et al.
Publicado: (2014)